Atlas Trials

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Clinical trial NCT06397222 · RECRUITING

Trial details

NCT number
NCT06397222
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma Non-resectable
Start date
2024-05-01
Primary completion
2027-04-30
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.